How India Exports Gliclazide to the World

As of March 2026, Gliclazide is not approved for use in the United States and does not have any approved Abbreviated New Drug Applications (ANDAs) listed in the FDA's Orange Book. Consequently, Gliclazide cannot be legally marketed or sold in the U.S. This regulatory status is crucial for Indian exporters, as it indicates that despite the substantial number of exporters (238) and shipments (3,830) globally, the U.S. market remains inaccessible for Gliclazide exports from India.

In the European Union, Gliclazide is authorized for the treatment of type 2 diabetes mellitus. Marketing authorizations are granted by the European Medicines Agency (EMA) and national regulatory authorities. Manufacturers must comply with EU Good Manufacturing Practice (GMP) guidelines to ensure product quality and safety. The United Kingdom, post-Brexit, follows a similar regulatory framework through the Medicines and Healthcare products Regulatory Agency (MHRA). Given that Hungary and the Netherlands are the top importers of Gliclazide from India, accounting for 29.3% and 29.2% of exports respectively, adherence to these regulatory standards is imperative for market access.

Gliclazide is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in managing type 2 diabetes globally. The drug is recognized in various pharmacopoeias, including the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), which set quality standards for its formulation and production. Compliance with these standards is essential for Indian exporters to meet international quality requirements.

In India, Gliclazide is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for its sale. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, Gliclazide is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national and international regulations.

The primary patents for Gliclazide have expired, leading to a competitive generic market. This patent expiration has facilitated the entry of multiple manufacturers, contributing to the substantial export figures from India. The presence of 238 active exporters indicates a highly competitive landscape, benefiting global markets through increased availability and potentially lower prices.

In June 2025, the NPPA announced a review of the pricing structure for antidiabetic medications, including Gliclazide, to ensure affordability and accessibility. This review could impact domestic pricing strategies for Indian manufacturers.

In September 2025, the EMA updated its guidelines on bioequivalence studies for generic medicines, emphasizing stricter compliance requirements. This development is particularly relevant for Indian exporters targeting the EU market, necessitating adherence to enhanced regulatory standards.

In December 2025, the WHO released the 22nd edition of its Model List of Essential Medicines, reaffirming the inclusion of Gliclazide. This inclusion highlights the drug's continued significance in global health initiatives and may influence procurement policies in various countries.

In February 2026, the CDSCO issued a circular mandating periodic stability studies for all exported pharmaceuticals, including Gliclazide, to ensure product efficacy throughout its shelf life. This directive aims to bolster the quality assurance framework for Indian pharmaceutical exports.

In March 2026, the DGFT introduced an online portal for the streamlined issuance of export NOCs, reducing processing times and enhancing compliance tracking for pharmaceutical exports. This initiative is expected to facilitate smoother export operations for Indian manufacturers.

These developments reflect a dynamic regulatory environment, underscoring the need for Indian exporters to stay informed and compliant with evolving standards to maintain and expand their global market presence.

India's pharmaceutical industry, including the production of Gliclazide, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of India's API and KSM requirements are sourced from China, making the supply chain vulnerable to disruptions. In September 2025, China implemented a significant price reduction of 40–50% on 41 APIs and KSMs, including those essential for Gliclazide production, aiming to undercut Indian manufacturers and challenge India's self-sufficiency initiatives.

This strategic pricing maneuver has placed Indian API producers under considerable financial strain, potentially leading to reduced domestic production capacity and increased dependency on Chinese imports. Such dependency exposes the Gliclazide supply chain to risks associated with geopolitical tensions, trade disputes, and supply interruptions originating from China.

The Gliclazide export market from India is highly concentrated, with the top five exporters controlling 83.0% of the market share. MYLAN LABORATORIES LIMITED alone accounts for 60.4% of exports, indicating a significant single-source risk. This concentration means that any operational, financial, or regulatory issues faced by these key exporters could substantially disrupt the global supply of Gliclazide.

To mitigate such risks, the Indian government has introduced the Production Linked Incentive (PLI) scheme aimed at boosting domestic API production and reducing reliance on imports. However, the effectiveness of this initiative is challenged by aggressive pricing strategies from Chinese manufacturers, which threaten the viability of new domestic API plants.

Recent geopolitical events have further complicated the Gliclazide supply chain. In February 2026, military conflicts led to the effective shutdown of the Strait of Hormuz, a critical passage for global oil and chemical shipments. This disruption has caused significant delays and increased transportation costs for pharmaceutical ingredients and finished products.

Additionally, tensions in the Red Sea and the Suez Canal have forced shipping companies to reroute vessels around the Cape of Good Hope, adding approximately 10 to 14 days to transit times. These extended shipping durations and increased costs have a cascading effect on the availability and pricing of pharmaceuticals, including Gliclazide.

• Diversify API and KSM Sources: Develop alternative suppliers in different geographic regions to reduce dependency on Chinese imports.

• Strengthen Domestic Production: Enhance the PLI scheme to support the establishment and sustainability of domestic API manufacturing facilities.

• Monitor Geopolitical Developments: Establish a dedicated task force to assess and respond to geopolitical events that may impact supply chains.

• Enhance Supply Chain Transparency: Implement advanced tracking systems to monitor the movement of raw materials and finished products, enabling proactive responses to disruptions.

• Establish Strategic Reserves: Maintain buffer stocks of critical APIs and finished products to cushion against short-term supply interruptions.

RISK_LEVEL: HIGH